Status: Recruiting
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass. The purpose of this study is to investigate the effect of ACM-001.1 (the study drug) on how much muscle is lost when a person takes it with semaglutide (PROACT 1) and how much muscle mass is gained when a person continues taking ACM-001.1 but stops taking semaglutide (PROACT 2).
Participants needed: 120
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Actimed Therapeutics LtdUpdated: Feb 17, 2026Locations: 7
Eligibility criteria
received a GLP-1RA (including semaglutide), [+3]